Association of Antiphospholipid Antibodies with Clinical Manifestations in Children with Systemic Lupus Erythematosus

被引:2
|
作者
Petrovic, Gordana [1 ]
Pasic, Srdjan [1 ]
Soldatovic, Ivan [2 ]
机构
[1] Mother & Child Hlth Care Inst, Belgrade 11000, Serbia
[2] Univ Belgrade, Sch Med, Belgrade 11000, Serbia
关键词
pediatric rheumatology; antiphospholipid antibodies; childhood SLE; SLEDAI; ANTICARDIOLIPIN ANTIBODIES; DAMAGE; RISK;
D O I
10.3390/jcm12041424
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Background: The aim of the study is to evaluate the effect of the presence of antiphospholipid antibodies on the clinical and laboratory manifestations, disease activity and outcomes of the disease in patients with childhood-onset systemic lupus erythematosus (cSLE). Methods: We conducted a 10-year cross-sectional study with a retrospective analysis of clinical and laboratory parameters and outcome of the disease (kidney, nervous system involvement, thrombosis). For the purpose of the study, patients were divided into cohort groups based on the presence of antiphospholipid antibodies (aPLA), named the aPLA positive group, or their absence, named the aPLA negative group. Values of aPLA were defined in reference laboratories. The disease activity was measured by the Systemic Lupus Erythematosus Disease Activity Index 2000 (SLEDAI-2K) score, whereas tissue damage degree was measured by Systemic Lupus International Collaborating Clinics/American College of Rheumatology-Damage Index (SLICC/ACR DI; SDI; DI). Results: Research in our center showed that patients with cSLE often had hematological, cutaneous, and non-thrombotic neurological manifestations. Antiphospholipid antibodies may be present transiently or permanently. A significant change in the titer value was observed in the IgG isotype of aCLA. The presence of higher values of IgM beta 2GP1 at the beginning indicates that higher disease activity can be expected. Higher disease activity correlates with greater tissue damage. Additionally, it has been shown that aPLA positive patients have two and a half times higher risk of tissue damage than aPLA negative ones. Conclusion: Our study shows that the presence of antiphospholipid antibodies in patients with childhood onset systemic lupus erythematosus may indicate a higher risk of tissue damage, but since it is a rare disease in childhood, prospective and multicenter studies are necessary to assess the importance of the presence of these antibodies.
引用
收藏
页数:9
相关论文
共 50 条
  • [41] Association of antiphospholipid antibodies and neuropsychiatric involvement in patients with systemic lupus erythematosus.
    Sanna, G
    Bertolaccini, ML
    Cuadrado, MJ
    Nurchis, P
    Khamashta, MA
    Mathieu, A
    Hughes, GRV
    ARTHRITIS AND RHEUMATISM, 2000, 43 (09): : S245 - S245
  • [42] Association of discoid lupus erythematosus with other clinical manifestations among patients with systemic lupus erythematosus
    Merola, Joseph F.
    Prystowsky, Stephen D.
    Iversen, Christina
    Gomez-Puerta, Jose A.
    Norton, Tabatha
    Tsao, Peter
    Massarotti, Elena
    Schur, Peter
    Bermas, Bonnie
    Costenbader, Karen H.
    JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY, 2013, 69 (01) : 19 - 24
  • [43] CHOREA IN SYSTEMIC LUPUS-ERYTHEMATOSUS AND LUPUS-LIKE DISEASE - ASSOCIATION WITH ANTIPHOSPHOLIPID ANTIBODIES
    ASHERSON, RA
    DERKSEN, RHWM
    HARRIS, EN
    BOUMA, BN
    GHARAVI, AE
    KATER, L
    HUGHES, GRV
    SEMINARS IN ARTHRITIS AND RHEUMATISM, 1987, 16 (04) : 253 - 259
  • [44] Antiphospholipid antibodies in children with systemic lupus erythematosus: a prospective study in northern India
    Ahluwalia, J
    Singh, S
    Garewal, G
    RHEUMATOLOGY INTERNATIONAL, 2005, 25 (07) : 530 - 535
  • [45] Antiphospholipid antibodies in children with systemic lupus erythematosus: a prospective study in northern India
    Jasmina Ahluwalia
    Surjit Singh
    Gurjeewan Garewal
    Rheumatology International, 2005, 25 : 530 - 535
  • [46] Antiphospholipid antibodies and cognitive dysfunction in systemic lupus erythematosus
    Barraclough, Michelle
    McKie, Shane
    Parker, Ben
    Elliott, Rebecca
    Bruce, Ian N.
    LUPUS, 2019, 28 : 22 - 22
  • [47] Anetoderma in systemic lupus erythematosus:: relationship to antiphospholipid antibodies
    Montilla, C
    Alarcón-Segovia, D
    LUPUS, 2000, 9 (07) : 545 - 547
  • [48] ANTIPHOSPHOLIPID ANTIBODIES IN PEDIATRIC SYSTEMIC LUPUS-ERYTHEMATOSUS
    SEAMAN, DE
    LONDINO, AV
    MANZI, S
    MEDSGER, TA
    ARTHRITIS AND RHEUMATISM, 1993, 36 (05): : R15 - R15
  • [49] Anetoderma associated with systemic lupus erythematosus and antiphospholipid antibodies
    Sabio, JM
    Tercedor, J
    Massare, E
    Jiménez-Alonso, J
    LUPUS, 2004, 13 (10) : 826 - 827
  • [50] Guidelines for looking at the antiphospholipid antibodies in systemic lupus erythematosus
    Stratta, P
    Canavese, C
    Ferrero, S
    Grill, A
    Piccoli, G
    NEPHRON, 1997, 76 (04): : 400 - 405